Diabetes and Renal Disease. PACE guidelines for Diabetes 2002 Renal/Hypertension.

• Slide 1

Diabetes and Renal Disease Slide 2 PACE guidelines for Diabetes 2002 Renal/Hypertension Slide 3 Annual dipstick for protein Positive Negative Exclude UTI and quantify Urine for ACR All patients with diabetes have an annual check for proteinuria and serum creatinine Slide 4 Proteinuria PCI 150-1000 Maximum tolerated dose of ACEI PCI >1000 Refer ACE inhibitors Slide 5 Albumin creatinine ratio > 2.5 on two occasions ACE inhibitors at max tolerated dose All patients continue to have annual check for proteinuria Slide 6 Serum Creatinine Check annually >150 refer to renal If Key Points from the Guidelines Proteinuria/ microalbuminuria ACE Inhibitors Early referral Creatinine (>150) Proteinuria (PCI >1000) Slide 8 The Nephrologists perspective The Final Common Pathway? Slide 9 Late Referral Mrs W, age 62 NIDDM 20years CHF Obesity TKR Wheelchair bound ESRF at referral Prognosis 98990001 Slide 10 Late Referral Within < 4 months of starting dialysis many patients suffer a needlessly rough journey on the road to dialysis Eadington Nephrol Dial Trans 1996 Slide 11 Late Referral QJM 2002 Bristol and Portsmouth 1997-8 38% new RRT patients referred late Nearly half were avoidable late referrals Poorer clinical state at start of RRT and likely worse outcome Slide 12 Late Referral Longer duration of predialysis nephrological care does improve outcome Jungers et al 2001 How long is longer? Slide 13 What are the benefits of earlier referral? or Slide 14 Slide 15 The DOPPS Study To what extent does vascular access account for mortality on dialysis? Slide 16 Late Referral in Bradford 13/35 new chronic HD patients referred late in 2001 Nephrologists are not blameless as only 8/35 commenced HD with a fistula Late referrals are more likely to be older, Asian and to have diabetes In all studies patients perceived as higher risk are referred late Slide 17 Earlier referral should improve subsequent mortality/morbidity of patients with ESRF due to diabetes Slide 18 Demographics Current take on rate in Bradford is approx 100 pmp Diabetes/hypertension/ESRF all more prevalent in South Asians Pending epidemic of type 2 diabetes DM 2x odds of death on dialysis cf non-diabetes Bradford dialysis cohort likely to double by 2010 Slide 19 Are we going to be able to dialyse our way out of trouble? Slide 20 Or is there another way? Slide 21 Is diabetic nephropathy preventable? Tight control Blood pressure Proteinuria ACE inhibitors Lipids Smoking cessation Slide 22 Blood pressure and proteinuria Reducing blood pressure slows the rate of disease progression Superiority of ACE Inhibitors Lewis et al NEJM 1993, Captopril Proteinuria is not just a disease marker but is pathogenetic Reduction in proteinuria slows progression Reviewed in lancet editorial 1999, DeJong et al Slide 23 Blood pressure and proteinuria Hovind Kidney International 2001 Normal progression of DN 10-12ml/min/year 7 year study of 300 type 1 patients 31% remission 22% regression (GFR decline 1ml/min/year) Even in this clinic many patients do not achieve BP targets Slide 24 Glycaemic control Prevention of microalbuminuria (PDS, DCCT) Little evidence for beneficial effect on progression of established DN although did predict regression in the Hovind study Limits other complications Patients who cannot achieve tight control still benefit from BP treatment Slide 25 Smoking and Lipids Meta-analysis suggests that lipid lowering can preserve GFR Renal function declines twice as fast in smokers This is under appreciated by patients and doctors Progression, remission, regression of chronic renal disease Ruggenenti, lancet 2001: 357 Slide 26 This is not reversible 5.4cm Slide 27 ESRF for average men and women Age60kg woman70kg man 207491033 30686947 40624861 50562775 60499689 70437603 80375516 Slide 28 Blood pressure Slide 29 Blood Pressure Initiate therapy if BP > 140/80 Aim for 130/80 or lower Follow PACE hypertension guidelines Slide 30 Anti-hypertensives in Diabetes Most patients will need several agents ACE inhibitors first line if ACR >2.5 Some contra-indications may be relative in diabetes Do not omit non-pharmacological measures Slide 31 Blood pressure treatment in normotensives? Schrier et al, Kidney International 2002 128/75 vs 137/81 Type 2 DM Reduced progression from normal to microalb to DN Reduced progression of retinopathy Reduced stroke Slide 32 ACE Inhibitor guidelines Check creatinine prior to prescribing Check creatinine approx 10 days after 1st dose Re-check after any dose increase Omit in the presence of intercurrent illness especially if dehydration/hypotension Higher degree of vigilance if PVD or other reason to suspect renovascular disease Slide 33 Any Questions?